Clinical Trial Update: Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating 12-week regimens of SOF/VEL/VOX fixed-dose combination and SOF/VEL in adults with chronic hepatitis C who have prior DAA exper…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• SOF/VEL (Sofosbuvir/Velpatasvir)
• SOF/VEL/VOX (sofosbuvir/velpatasvir/voxilaprevir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2017-11-06